← Back to Search

Pulmonary Artery Shunt

Rivet Shunt for Pulmonary Hypertension with Heart Failure

N/A
Waitlist Available
Research Sponsored by NXT Biomedical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new treatment called Rivet PVS therapy to see if it is safe and effective. It focuses on patients who have high blood pressure in their lungs that causes symptoms. The goal is to find out if this new therapy can help reduce their symptoms.

Eligible Conditions
  • Congestive Heart Failure
  • Heart Failure
  • Pulmonary Hypertension

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rate of Major Adverse Events
Rate of Technical Success of the Rivet Shunt Implantation Procedure
Secondary study objectives
Adverse Events through 12 months
Change in Hemodynamics at 12 months - PCWP
Change in Hemodynamics at 12 months - mPAP/CO Slope
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Rivet Shunt TherapyExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

NXT BiomedicalLead Sponsor
1 Previous Clinical Trials

Media Library

Rivet PVS Therapy (Pulmonary Artery Shunt) Clinical Trial Eligibility Overview. Trial Name: NCT05205265 — N/A
Congestive Heart Failure Research Study Groups: Rivet Shunt Therapy
Congestive Heart Failure Clinical Trial 2023: Rivet PVS Therapy Highlights & Side Effects. Trial Name: NCT05205265 — N/A
Rivet PVS Therapy (Pulmonary Artery Shunt) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05205265 — N/A
~0 spots leftby Dec 2025